Joe Beechem, Chief Scientific Officer and Senior Vice President at Bruker Spatial Biology, shared a post on LinkedIn:
“What happens when you ‘team-up’ whole transcriptome sub-cellular multiomic imaging (CosMx WTX, Joe Beechem-lab at Bruker) and state-of-the-art CRISPR-based Drug Discovery (Vanessa Peterson lab at Merck)?
Well…you get ORGANOIDS from (outer) SPACE (SPAtial Cell Exploration)!
Check-out this Biorxiv pre-print, where cancer-associated-fibroblasts (CAFs) are Crispr-edited, then (at high-throughput) CAF-Tumor-cell organoids are made and subcellularly imaged in 3D at ~ 19000-plex mRNA and 68-plex protein. This scalable, cost-effective (~ 1-cent per cell) technology has broad applications in translational research and drug discovery, offering a transformative approach to high-throughput spatial perturbation studies of all kinds.”
Title: SPACE: spatially resolved multiomic analysis for high-throughput CRISPR screening in 3D models.
Authors: Mengwei Hu, Yi Cui, Qianhui Huang, Khoi Chu, Sierra McKinzie, Michael Patrick, Sharanya Iyengar, Maerjianghan Abuduli, Marianne Spatz, Nandita Joshi, Brendan Miller, Shams Vellarikkal, Timothy Riordan, Danny Bitton, Jan Lubojacky, Iya Khalil, Federica Piccioni, Michael Rhodes, Alex Tamburino, Shanshan He, Joseph Beechem, Vanessa Peterson.
Read more about CRISPR, on OncoDaily.